These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 21900727

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
    Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R.
    Virology; 2010 Jul 05; 402(2):338-46. PubMed ID: 20421122
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
    Fun A, Van Baelen K, van Lelyveld SF, Schipper PJ, Stuyver LJ, Wensing AM, Nijhuis M.
    J Antimicrob Chemother; 2010 Nov 05; 65(11):2300-4. PubMed ID: 20736234
    [Abstract] [Full Text] [Related]

  • 28. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
    Hu Z, Kuritzkes DR.
    J Acquir Immune Defic Syndr; 2010 Oct 05; 55(2):148-55. PubMed ID: 20634701
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
    Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L, Mouscadet JF.
    Antimicrob Agents Chemother; 2010 Jan 05; 54(1):491-501. PubMed ID: 19901095
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
    Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG.
    J Antimicrob Chemother; 2009 Apr 05; 63(4):795-804. PubMed ID: 19221102
    [Abstract] [Full Text] [Related]

  • 36. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
    Buzón MJ, Dalmau J, Puertas MC, Puig J, Clotet B, Martinez-Picado J.
    AIDS; 2010 Jan 02; 24(1):17-25. PubMed ID: 19770695
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
    Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S.
    Clin Infect Dis; 2015 May 15; 60(10):1521-7. PubMed ID: 25690598
    [Abstract] [Full Text] [Related]

  • 40. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
    Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, Guiguet M, Tubiana R, Canestri A, Valantin MA, Peytavin G, Pacanowski J, Morand-Joubert L, Calvez V, Girard PM, Katlama C.
    Scand J Infect Dis; 2010 Jul 15; 42(6-7):527-32. PubMed ID: 20222846
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.